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Summary 
The influence of endogenous and exogenous tumor  necrosis factor (TNF)  on metastasis was 
investigated in an experimental fibrosarcoma metastasis model. A single intraperitoneal injection 
of recombinant human (rh) TNF or recombinant mouse (rm) TNF into mice 5 h before intravenous 
inoculation  of methylcholanthrene-induced  fibrosarcoma  cells  (CFS1)  induced  a  significant 
enhancement  of the number of metastases in the lung.  Dose responses of rmTNF and rhTNF 
demonstrated a stronger metastasis-augmenting  effect by rmTNF compared with rhTNF.  This 
effect was time dependent,  as administration  of rmTNF 5 h before or 1 h but not 24 h  after 
tumor cell inoculation caused an increase of tumor cell colony formation on the lung surface, 
suggesting an influence of TNF on the vascular adhesion and diapedesis of tumor cells.  Since 
tumor-bearing mice showed an enhanced ability to produce TNF after endotoxin injection compared 
to control mice, tumor-bearing mice were treated with anti-mTNF  antibodies.  Neutralization 
of endogenous tumor-induced  TNF led to a significant decrease of the number of pulmonary 
metastases.  Histological analysis  of micrometastases in the lung on day 5 by silver staining of 
proteins associated with nucleolar organizer regions revealed more metastatic loci and augmented 
proliferative activity of the tumor cells after rmTNF pretreatment  of mice. However, no direct 
effect of rmTNF on the proliferation rate of tumor cells was seen in vitro. These findings suggest 
that low doses of endogenous TNF or administered TNF during cytokine therapy might enhance 
the metastatic potential  of circulating  tumor cells. 
T 
NF, a cytokine predominantly produced by activated mac- 
rophages, exerts a cytotoxic or cytostatic effect on some 
tumor cell lines in vitro and has the capacity to induce necrosis 
of solid tumors in some animal models (1-4). TNF has,  in 
addition to the antitumor effects,  a broad spectrum of bio- 
logical activities,  implicating  a major role in immune  and 
inflammatory  responses.  For  instance,  TNF  induces  the 
production of IL-1 (5),  IFN-/S (6), as well as CSF (7)  and 
enhances  the expression of HLA genes in tumor cells  (8). 
Furthermore, TNF stimulates cells to express cell-surface adhe- 
sion  molecules  such  as  intercellular  adhesion  molecule  1 
(ICAM-1) (9, 10), vascular cell adhesion molecule 1 (11, 12), 
and endothelial leukocyte adhesion molecule 1 (13). Because 
of some of these actions, TNF has beneficial antitumor  ac- 
tivity (1, 2). However, TNF might also contribute to tumor 
progression.  TNF is able to induce enzymes that  may en- 
hance tumor spread, e.g., collagenases (14), to stimulate an- 
giogenesis in vivo (15),  to stimulate bone resorption  (16), 
and to increase the adherence of tumor cells to endothelium 
in vitro (17-19). It has also been shown that TNF promotes 
the invasive  growth  of tumor cells in  the peritoneum  and 
their establishment as tumor nodules below the mesothelial 
surface (20, 21). The role of endogenous TNF in the patho- 
physiology of cancer and metastasis is still controversially dis- 
cussed and only limited information is available demonstrating 
enhanced TNF levels in the serum  of cancer patients  (22, 
23) and tumor-bearing animals (24, 25). We therefore inves- 
tigated  the effects of exogenous and endogenous  TNF  on 
metastasis  in an experimental  tumor  model in mice. 
Materials  and Methods 
Mice.  Female  C3H/He and female DBA/2 mice 5-7 wk of age 
were obtained from the Institut fOr Versuchstierforschung (Han- 
hover, FRG). The animals were kept in the central animal facility 
of the German Cancer Research Center under specific-pathogen- 
free conditions  throughout the experiments. 
Cell Cultures.  CFS1  is a methylcholanthrene-induced  fibrosar- 
coma cell line of C3H/HeN mouse origin, generated and kept at 
the German  Cancer  Research Center.  ESb, a highly  metastatic 
subline  of the  methylcholanthrene-induced  DBA/2 lymphoma 
L5178YE feb), was kindly provided by V. Schirrmacher (German 
Cancer Research Center). L929 is a TNF-sensitive mouse fibrosar- 
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with 10% heat-inactivated FCS, 5 mM Hepes, and 100 IU/ml pen- 
icillin-0.1 mg/ml streptomycin (all from Gibco, Eggenstein, FRG), 
in a humidified atmosphere containing  5%  COs at 37~  Cul- 
tures were routinely verified as being mycoplasma free. The tests 
were performed with a mycoplasma-DNA hybridization kit accord- 
ing to the manufacturer's instructions (Gen Probe, San Diego, CA). 
Reagents.  Recombinant human (rh)lTNF-c~ (9  x  llY U/mg 
sp act) and recombinant mouse (rm)TNF-cr (8  ￿  107 U/mg sp 
act) were a generous gift from BASF/Knoll AG (Ludwigshafen, 
FRG). The rat anti-mouse TNF mAb VIQ was purified as previ- 
ously described (26). Briefly, serum-free hybridoma supernatant was 
precipitated at 45% ammonium sulfate saturation. The precipitated 
material was centrifuged at 15,000 g, dissolved  in 10 mM NaC1/ 
50 mM Tris/HC1, pH 8, and dialyzed against this buffer. This buffer 
was also  used  as  the  starting buffer for anion  exchange HPLC 
(Spherogel TSK DEAE-SPW; Beckman, Mfinchen, FRG). The ma- 
terial was applied to the HPLC column in a volume of 10 ml at 
a flow rate of 1 ml/min.  The column was washed with loading 
buffer until baseline absorption at 280 nm was reached. The ad- 
sorbed material was eluted using a linear gradient from 10 to 300 
mM NaC1 in 50 mM Tris/HCL pH 8.  1-ml fractions were col- 
lected and the TNF neutralizing capacity was measured using the 
L929 TNF bioassay.  The most active fractions were pooled and 
dialyzed against PBS. R4-6A2,  a rat anti-IFN-7 mAb (27),  was 
precipitated from serum-free hybridoma supernatant at 45% am- 
monium sulfate saturation, centrifuged, dissolved in distilled water, 
and dialyzed against PBS. Polyclonal  rat IgG and LPS (from Sal- 
monella minnesota) were purchased from Sigma Chemical Co. (St. 
Louis,  MO). 
Quantitation of  Experimental Metastases.  CFS1 tumor cells were 
harvested by exposure to 0.05%  trypsin-0.02%  EDTA solution 
(Gibco), washed twice, and resuspended in HBSS. The suspension 
was filtered through a cell strainer (Becton Dickinson & Co., Lin- 
coln  Park,  NJ)  and  adjusted  to  a  concentration  of 1.5  x  106 
cells/ml 0.2 ml (3  x  10  s CFS1 cells) of the single cell suspension 
(>90%  viability by trypan blue exclusion)  was injected into the 
lateral tail vein of C3H mice. Animals were killed by cervical dislo- 
cation on day 11 or 12. After staining by endotracheal infiltration 
with  15% china ink solution (Rotting Werke Riepe KG, Ham- 
burg, FRG), lungs were removed, fixed,  and bleached in Fekete's 
solution  (28).  The  number  of macroscopic  pulmonary  tumor 
nodules was counted in each of the five lobes. 
The nonadherent ESb cells were washed twice and resuspended 
in HBSS.  105 cells/0.2 ml were injected into the lateral tail vein of 
DBA/2 mice. Mice were killed at day 4,  and the livers were re- 
moved and fixed in 4% buffered formalin. Paraffin sections were cut 
and stained with haematoxylin-eosin. Liver metastases were deter- 
mined by counting the metastatic loci under  the microscope. 
Induction of TNF Production.  At the indicated days, mice were 
injected intraperitoneally with 10 #g LPS in 0.2 ml PBS 1.5 h be- 
fore blood collection. 
Preparation of  Serum.  Blood samples collected from the tail vein 
were allowed to clot at room temperature for 15 min and were 
then kept at 4~  for at least I h. Sera were clarified by centrifuga- 
tion (5,000 rpm for 2 min) and stored at  -20~  until needed. 
L929  TNF Bioassay.  The assay was performed as previously 
described (29).  Briefly,  2.2  x  104 L929 cells/100/~1  per well of 
a 96-well microtiter plate were incubated overnight. After replacing 
1 Abbreviations used in this paper: AgNOR, nudeolar  organizer regions 
demonstrated by silver  staining; rhTNF, recombinant human tumor necrosis 
factor; rmTNF, recombinant mouse tumor necrosis factor. 
the  culture  medium  with  medium  containing  2  #g/ml  of ac- 
tinomycin D (Sigma Chemical Co.), 100/xl of serum (diluted 1:4 
with PBS) was added and sequential twofold dilutions were made. 
After 18 h of incubation at 37~  remaining cells were stained with 
crystal violet (Sigma Chemical Co.). After washing, the stain was 
dissolved in 33% acetic acid (100 #1) and the OD at 550 nm was 
determined using an ELISA reader (Easy Reader EAR 400;  SLT- 
Labinstruments, Grrding, Austria). An internal rhTNF-c~ standard 
was included in each assay. 
Measurement of Tumor Cell Proliferation In Viva  Silver staining 
of argyrophilic proteins associated with nucleolar organizer regions 
(AgNOR),  whose number and size correlate with cell prolifera- 
tion and differentiation,  was performed as described previously (30). 
Briefly, lungs were removed at the indicated times and fixed in 4% 
buffered formalin. Paraffin sections were cut at 3-4/~m onto glass 
slides.  These were  dewaxed  in  xylene  and  rehydrated  through 
descending concentrations of ethanols to distilled,  deionized water. 
The staining time was about 26 min and the silver staining was 
carried out in the dark. The AgNOR were evaluated by means 
of a digital image analysis system (Cue2; Olympus Optical Corp., 
Hamburg, FRG). At least 50 cells of each slide were examined, 
choosing fields at random and avoiding nontumorous areas. The 
mean number of AgNOR per cell (N),  and the mean AgNOR 
area per silver stained NOR particle (A) were calculated as follows: 
N  =  No. AgNOR/No. cells; A  =  area ofAgNOR/No. AgNOR. 
Since the NOR number and area are inversely correlated, the ratio 
of these  two  parameters was regarded  as  an  equivalent  of the 
AgNOR content of a given cell  (C  =  N/A).  Since  the area of 
AgNOR  is  in  the  range  of 0.1-2  /zm  ~,  a  relatively high  final 
magnifcation of 4,000 was used on the monitor of the image ana- 
lyzer; the microscope magnification was 1,000.  To minimize the 
problem of nucleolus-biased sampling, the measuring field of the 
image digital video board was reduced to a central portion, so that 
only one or two cells could be measured at once. 
StatisticalAnalysis.  The probability of significant differences be- 
tween groups was determined by Student's t test. Differences in 
the numbers of lung colonies and AgNOR content were analyzed 
using the Mann-Whitney U  test.  Results are representative of at 
least two different experiments. 
Results 
Endotoxin-induced  TNF Production after Intravenous Inocula- 
tion of Tumor Cells.  Mice were injected with endotoxin  in 
order to determine whether tumor-bearing mice show an in- 
creased capacity to produce TNF. Fig. 1 shows that 3 d after 
injection of CFS1 tumor cells, mice had enhanced serum TNF 
levels in response to LPS compared with control mice. A second 
peak developed on day 12.  Endotoxin-induced  serum TNF 
levels before day 3 and on days 6 and 9 after tumor implanta- 
tion did not differ from endotoxin-induced serum TNF levels 
of normal  mice. 
Effects of rmTNF and rhTNF on the Number of Metastases. 
Since tumor-bearing mice had a higher capacity to produce 
TNF,  we investigated whether  exogenous TNF  would  in- 
fluence the number of lung metastases. Mice were inoculated 
intravenously with CFS1 tumor cells. 5 h before inoculation, 
they were injected  intraperitoneaUy with  10/~g per mouse 
of either rmTNF or rhTNF. After 12 d, mice were killed and 
the pulmonary metastases were counted. Fig. 2 shows a dra- 
matic increase in the number of metastases in TNF-treated 
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mice. Histological examinations  revealed no metastases in other 
organs. To exclude that this effect was due to contaminating 
LPS in the TNF preparations,  the preparations were heated 
to 100~  for 15 min.  This treatment  completely destroyed 
their  metastasis-enhancing  capacity (data  not  shown). 
The augmentation  of the number of tumor colonies on 
the surface of the lung was greater with increasing concen- 
trations of rTNF (Fig. 3). The figure also shows that rmTNF 
had a two- to fivefold higher capacity to enhance the metastatic 
potential  of tumor cells  than  had rhTNF.  Whereas 0.4 #g 
rhTNF  (mean number of metastases  _+  SEM [range]:  33.2 
_+  7.9  [5-56])  had  no  influence  on  the  number  of lung 
metastases on day 11, 0.4 #g rmTNF (82.0  _+  13.4 [28-123]) 
already caused a significant increase. Pretreatment of the mice 
with 25 #g rhTNF (197.7  +  15.4 [135-250]) resulted in an 
equally significant  enhancement of metastases  as pretreatment 
with  10 #g rmTNF  (221  _+  18  [145-250]). 
To investigate the time course of rmTNF-induced augmen- 
tation of lung metastasis,  mice were injected intraperitoneaUy 
with 7.5 #g rmTNF at various times before and after intra- 
venous tumor cell implantation. Fig. 4 shows that a significant 
increase of tumor colonies on the lung compared with con- 
trol mice was only observed when  rmTNF  was given 5  h 
before (185.7  +  31.7  [86-250])  or  1 h  after (169.3  _+  4.3 
[151-182]) CSF1 tumor cells. No significant  influence on lung 
colony formation was seen when TNF was given 24 h before 
Figure  1.  Time course of endotoxin-induced TNF production in tumor- 
bearing mice. At the indicated times after intravenous CFS1 tumor cell 
injection, 10 #g endotoxin/200 #1 PBS was injected intrapetitoneaUy.  Serum 
was obtained 1.5 h later and TNF levels were determined by L929 TNF 
bioassay.  Results are expressed as mean  +  SEM of five mice per tumor- 
beating group. Control groups (C) n  =  13. (* *)p <0.005; (*)p <0.025. 
Figure  2.  Enhancement of experimental lung metastasis by 
rmTNF and rhTNE  Mice received single intrapetitoneal in- 
jections of 10/zg rmTNF/mouse.  10 #g rhTNF/mouse,  or 
100 #1 PBS 5 h before tumor cell injection (3  x  10  s CFS1 
fibrosarcoma cells intravenously). Lungs were stained on day 
12 and metastases were counted.  Representative lungs taken 
from  one  experiment  are  shown.  (~y)  PBS  pretreatment 
(n  =  10); (center) fmTNF (n  =  6); (bottom) rhTNF (n  =  6). 
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Figure  3.  Increase of experimental lung metastasis by different concen- 
trations of rmTNF and rhTNF. Mice were given intraperitoneal injections 
of different concentrations of rmTNF  or rhTNF  5  h  before intravenous 
CFS1  tumor cell injection (3  x  10s).  Control  mice received the  same 
volume of PBS. Results are expressed as mean  _+ SEM. n  =  12 for control 
group; n  =  6 for TNF-treated groups.  (* * *) p  <0.001;  (* *) p  <0.005; 
(*) p  <0.05. 
or 24 h up to 4 d after tumor cell injection. In control mice 
46.2  +  10.2 (1-99)  metastases  were counted per lung. 
To obtain information  whether these effects were host medi- 
ated or due to a direct influence of TNF on the tumor cells, 
CFS1 cells were cultured for 24 h with rmTNF (0.2 #g/ml) 
or rat anti-mTNF mAb (V1Q)(0.8  #g/ml) at 37~  After 
trypsinizing and washing, 3  x  10  s cells were injected in- 
travenously in untreated mice. On day 12 after tumor cell 
implantation, the number of lung metastases from mice given 
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Kinetics of rmTNF-induced enhancement of lung metastasis.  Figure  4. 
rmTNF (7.5 #g/mouse i.p.) was administered at different times before or 
after intravenous injection of 3  x  10  s CFS1  tumor cells.  Lungs were re- 
moved and stained on day  11.  Results  are expressed  as mean  +  SEM. 
n  =  6 for TNF-treated groups; n  =  12 for control group (C). (*)p  =  0.001. 
rmTNF- or VIQ-pretreated tumor cells was not significantly 
different  compared with the control group (data not shown). 
In a second metastasis model, application of 10 #g rmTNF 
intraperitoneally  5  h  before intravenous inoculation  of 10  s 
ESb cells caused an approximately threefold enhancement of 
tumor infiltrates  into the liver (mean number of metastases/ 
mm  2  _+  SEM:  0.85  _+  0.098)  compared  with  the  control 
group (0.31  +  0.077) (data not shown). 
Decrease  of  Metastasis by Neutralization  of  Endogenous TNE 
As tumor-bearing mice showed an enhanced capacity for TNF 
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Figure  5.  Decrease of lung metastasis by neu- 
tralization of endogenous TNE  Rat anti-mTNF 
mAb (40 #g) or PBS were injected intraperitoneaUy 
5  h  before intravenous CFS1  tumor cell inocula- 
tion. Mice were autopsied on day 12. Representa- 
tive lungs taken from one experiment are shown. 
(Tbp) PBS pretreatment (n -  10); (bottom) rat anti- 
mTNF  mAb treatment  (n  =  6). Table  1.  Reduction of Experimental Metastasis by Neutralization 
of Endogenous TNF 
No.  of lung  metastases 
Pretreatment  n  Mean  _+  SEM  Range  p 
PBS-control  8  58.5  +  7.9  22-82 
Rat  anti-mTNF 
mAb (VIQ)  6  9.6  _+  5.6  1-31 
Rat  anti-mlFN-3~ 
mAb (R4-6A2)  6  48.7  _+  16.3  0-116 
Rat  IgG  6  66.9  _+  18.0  23-114 
<0.005 
Table  2.  Enhancement  of the Tumor Cell Proliferation Rate 
In  Vivo by rm TNF 
Pretreatment 
AgNOR  parameter  PBS  control  rmTNF  p 
No.  of AgNOR/ 
cell  1.2  _+  1.2"  8.4  _+  0.7  <0.001 
AgNOR  area 
(/~m2)/AgNOR  0.02  +  0.02  0.13  +  0.01  <0.001 
AgNOR content/ 
cell  9.4  +  9.4  65.8  +_  5.6  <0.001 
Mice were treated intraperitonally with the indicated substances 5 h be- 
fore intravenous CFS 1 tumor cell injection (3  x  10s). Animals were 
killed on day 11,  the lungs were removed, and the number of surface 
colonies was counted. 
Mice received 10/~g rmTNF or 100 #1 PBS 5 h before intravenous tumor 
cell inoculation. Lungs were removed on day 5, fixed in formalin, and 
the AgNOR parameters were determined. 
" n  =  6 per group;  data represent mean  _+ SEM. 
production  and  since exogenous  TNF  increased metastasis, 
we investigated the influence of endogenous TNF on the for- 
mation  of lung  metastases.  Mice  received  a  single  intra- 
peritoneal injection of 40/~g of rat anti-mTNF mAb (VIQ) 
in 0.2 ml PBS 5 h before CFS1 tumor cell inoculation.  Con- 
trol mice received either polyclonal rat IgG (100/~g) or 0.2 ml 
PBS. After 11 d, tumor cell colonies on the lung surface were 
counted.  Fig.  5  and  Table 1  show  a  significant  decrease  of 
metastasis in the anti-mTNF pretreated group in comparison 
with  the  control  IgG- and  PBS-treated  mice. 
As IFN-y is able to enhance LPS-induced  TNF  produc- 
tion of macrophages (31), we examined whether endogenous 
IFN-3' might also be involved in the enhancement of metastasis 
induced  by endogenous  TNF.  For  that  purpose,  rat  anti- 
mlFN-3, mAb (R4-6A2) was administered 5 h before tumor 
cell inoculation.  As can be  seen in  Table  1,  this  mAb was 
not effective in preventing the formation of tumor cell colo- 
nies  on  the lung,  in contrast  with  the mTNF-neutralizing 
mAb  V1Q. 
Augmentation  by rmTNF of Tumor Cell Proliferation In Viw 
One possible reason for finding more and larger tumor cell 
colonies on the lung surface in ffNF-treated mice could be 
Figure  6.  (a) Histological section of lung  tissue exhibiting small metastatic tumor nodules within  alveolar septae (arrows). Terminal broncheolus 
without pathological changes (*). (Haematoxylin/eosin stain, original  x200).  (b) Nodule of metastatic tumor cells showing multiple silver-stained 
NOR dots (AgNOR) within nuclei (arrows). (AgNOR stain, original  x 1,000). 
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able parameter for in vivo proliferation is the number and size 
of silver-stained proteins associated  with AgNOR per cell 
(30).  Therefore, we investigated the effect of 10 #g rmTNF 
given 5 h before intravenous CFS1  tumor cell inoculation 
on the AgNOR parameters per tumor cell. The lungs were 
removed on day 5 and the AgNOR parameters were deter- 
mined on paraffin sections by digital image analysis. Sections 
from the lungs  of rmTNF-pretreated mice showed a  sig- 
nificantly enhanced number of AgNOR dots, AgNOR area, 
and  AgNOK  content per cell,  indicating  an  augmented 
proliferation rate compared with the PBS-treated control group 
(Fig.  6,  Table 2).  AgNOR parameters measured on day 7 
after tumor cell inoculation showed a comparable result (data 
not shown). This effect ofrmTNF on CFS1 tumor cells seems 
to be specific for in vivo conditions for we could not demon- 
strate any influence ofrmTNF on CFS1 proliferation in vitro 
measured by [3H]thymidine incorporation (data not shown). 
Discussion 
The influence of exogenous TNF  administered during 
cytokine therapy and of endogenous TNF produced, for ex- 
ample, by tumor-infiltrating macrophages and peripheral blood 
monocytes on the metastatic behavior of circulating tumor 
cells is of considerable importance. In this study we have shown 
that rmTNF and rhTNF injected 5 h before intravenous in- 
oculation of CFS1 fibrosarcoma cells caused a significant aug- 
mentation of pulmonary metastases. Similarly, application of 
rmTNF before intravenous injection of ESb cells resulted in 
an increase of liver metastases.  In addition, we do have pre- 
liminary data indicating that enhanced metastasis occurs under 
the influence of TNF when the metastasizing tumor cells 
started from a solid primary tumor nodule, e.g., Lewis lung 
carcinoma or ESb (our own unpublished results). 
The effect of TNF on CFS1 cells was dose dependent and 
rmTNF revealed a higher metastasis-enhancing activity than 
did rhTNF. Increased formation of tumor cell colonies on the 
lung was only seen when rmTNF was given 5 h before or I h 
after,  but not 24 h  or later after tumor cell implantation. 
Tumor cells in TNF-pretreated mice showed an enhanced pro- 
liferation rate as determined by the number of AgNOR dots. 
Accordingly, neutralization of endogenous tumor-induced 
TNF led to a decrease of the number of lung metastases. 
Augmented serum TNF levels in tumor-bearing mice after 
LPS injection have also been shown in other studies (24, 25). 
However, the time course of TNF production was different, 
suggesting an influence of tumor cell immunogenicity, the 
way of application, and/or the mouse strain used on TNF 
secretion. In this study, endogenous TNF production peaked 
at day 3 after tumor cell injection (Fig.  1). With respect to 
the metastasis-enhancing effect of TNF, this finding does not 
correlate with the observation that TNF led to an augmen- 
tation of tumor cell colonies on the lung surface only when 
given 5 h before or 1 h after, but not 3 d  after tumor cell 
inoculation (Fig. 4). A possible explanation for this finding 
could be that 1 h after tumor implantation, when TNF exerts 
its metastasis-enhancing effect, tumor-induced TNF either 
remained membrane bound or was only present in very low 
amounts and thus was not detected in the serum with our 
TNF  assay system. 
Nevertheless, a critical role of endogenous TNF on the 
formation of pulmonary metastases was demonstrated by using 
anti-mTNF mAb. Neutralization of endogenous TNF caused 
a significant decrease of tumor cell colonies on the lung sur- 
face (Table 1, Fig. 5). Few other studies indicate a contribu- 
tion of endogenous TNF to the metastatic behavior of tumor 
cells. Malik et al. (21) transfected Chinese hamster ovary cells 
with the gene for hTNF and showed that these TNF-secreting 
cells exhibited a greatly enhanced ability to invade peritoneal 
surfaces. Even though this experimental design differs from 
our study with host-produced endogenous TNF, it demon- 
strates TNF-caused increased capacity of tumor cells for in- 
vasive growth. 
Experiments concerning the influence of exogenous TNF 
on metastasis had rather controversial results. Tomazic et al. 
(32) noted that TNF inhibited the development of pulmo- 
nary metastases in a murine fibrosarcoma model if TNF was 
injected within 3 d of tumor cell inoculation. Similar results 
were described in a murine lung cancer model (33) and in 
a murine melanoma model (34). On the other hand, adminis- 
tration of hTNF led to an increase in the number of pulmo- 
nary metastases when given together with tumor cells (35) 
or 1 h before intravenous inoculation of a human melanoma 
cell line (36).  Furthermore, hTNF promoted the implanta- 
tion of human ovarian cancer xenografts in the peritoneal 
cavity, leading to a pathological appearance similar to that 
of metastatic human cancer (20). The latter findings confirm 
our results revealing an increased metastatic capacity of tumor 
cells induced by TNF. 
As shown in Fig. 3, rmTNF exhibited a higher metastasis- 
enhancing capacity than rhTNF. This fact is not surprising 
considering the partial species specificity of TNF (37, 38). 
In addition, it is conceivable that the effect of enhanced tumor 
cell colony formation on lungs of mice is in part mediated 
via the type II TNF receptor (75 kD) which binds mTNF 
species specifically (TNF receptors reviewed in reference 39). 
A variety of mechanisms can be envisaged to play a role 
in the metastasis-augmenting activity of TNF. Metastasis  is 
a complex process involving the release of tumor cells from 
a primary tumor entering of the vascular or lymphatic circu- 
lation  and extravasation  to  specific  sites  distant  from the 
original tumor. These processes  require tumor cell attach- 
ment to the endothelium of vessels or capillaries before they 
can perform diapedesis and migrate through the vessel wall. 
Morphological studies on the interaction ofintravascular tumor 
cells with endothelial cells revealed an initial tumor cell ar- 
rest with extensive contact to the endothelial cells during the 
first 8 h after intravenous tumor cell injection (40). Penetra- 
tion by arrested tumor cells of vascular endothelial cell junc- 
tions commenced already after 4 h and intravascular prolifer- 
ation  was  first  noted  24  h  after the initial  arrest  of the 
circulating tumor cells. Our results showing enhancement 
of metastasis by endogenous TNF and by exogenous TNF 
given 5 h before or 1 h after but not 24 h after tumor cell 
injection indicate an influence of TNF on one of the above 
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experiments demonstrating an increased expression of cell sur- 
face adhesion molecules (9-13) and an augmented adherence 
of tumor cells to endothelial  cell lines  (17-19) induced by 
TNF. Miyata et al. (35) recently reported that a TNF mutein 
with  a  laminin-derived  cell-adhesive  peptide  reduced  ex- 
perimental  pulmonary  metastases in contrast  to wild type 
TNF.  Furthermore,  Giavazzi et al.  (41) demonstrated  that 
TNF  and  other  cytokines  induced  the  release  of soluble 
ICAM-1 by tumor cells in vitro and that the serum level of 
ICAM-1  in nude mice showed a positive correlation  with 
the tumor weight,  suggesting an involvement of ICAM-1 
release in the recognition of the tumor by the immune system. 
A further possible mechanism leading to more and larger 
pulmonary metastases relies on an enhanced proliferation rate 
caused by TNF of the extravasated tumor cells. The number 
and content (ratio of number and area) of silver-stained pro- 
teins associated with AgNOR correlate with the cell prolifer- 
ation (30).  R/ischoff et al.  (30) demonstrated  a significant 
correlation  between the AgNOR number  and tumor cell 
proliferation,  as determined by staining of tumor cells with 
Ki67, an immunohistochemical proliferation marker. Similar 
results  were reported  for neuroblastoma cell lines  (42).  In 
Table 2 we show that TNF treatment led to an increase of 
the AgNOR parameters in tumor cells 5 d after tumor im- 
plantation,  indicating an augmented metabolic and prolifer- 
ative activity. This effect was host dependent, for we could 
not demonstrate any influence of rmTNF on the tumor cell 
proliferation in vitro when tritiated  thymidine uptake was 
measured (data not shown). However, recent data by Lollini 
et al. (43) demonstrated that TNF can enhance the metasta- 
sizing capacity by direct action on the tumor cells.  In our 
experimental system, we did not see such an effect after pre- 
treatment of tumor cells with TNF in vitro before inoculation. 
Recent  reports  of a  positive  correlation  of stimulated 
immune status determined by enhanced levels of neopterin, 
a macrophage-derived product,  and IL-6 in tumor patients 
with bad prognoses and enhanced metastases are well in line 
with the data obtained in this study (44, 45). The observa- 
tions reported here,  enhancement  of metastasis by endoge- 
nous and exogenous TNF and increased tumor cell prolifera- 
tion in vivo induced by TNF treatment, suggest a promoting 
activity of TNF on the secondary spread of neoplastic cells 
and recommend a careful administration  of this cytokine in 
cancer therapy. 
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